Physician profile
Heather M Miles
NPI 1942749015
$8,866.90
in general payments reported to CMS, 2019-2025
56 companies · $1,556 in 2025
The $1,556 reported for 2025 was more than what 92% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,031 · 2022: $1,546 · 2023: $1,783 · 2024: $1,951 · 2025: $1,556.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,276 · Education: $14.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,276.45 |
| Education | $14.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,712.82 | 2021-2025 | |
| Lilly USA, LLC | $882.89 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $753.13 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $658.05 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $405.28 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $403.82 | 2021-2023 | Trintellix |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $370.11 | 2021-2025 | Caplyta |
| Xeris Pharmaceuticals, INC. | $305.90 | 2024-2025 | Keveyis, Gvoke Hypopen |
| Astrazeneca Pharmaceuticals Lp | $277.06 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Axsome Therapeutics, INC. | $246.61 | 2023-2025 | Symbravo, Auvelity, Sunosi |
| Esperion Therapeutics, INC. | $226.06 | 2021-2025 | Nexletol |
| Amarin Pharma, INC. | $212.17 | 2021-2023 | |
| Antares Pharma, INC. | $197.08 | 2021-2024 | Xyosted, Nocdurna, Tlando |
| Glaxosmithkline, LLC. | $146.27 | 2021-2024 | Arexvy, Trelegy Ellipta, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $133.85 | 2021-2025 | Synjardy, Jardiance, Ofev |
Show all 56 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heather Miles listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.